Response Rates Rule In CGRP Inhibitor Migraine Studies

The primary endpoint in CGRP inhibitor trials is the average reduction in monthly headache days, but the scientific program committee chair for the recent American Headache Society meeting told Scrip that response rates are more important for doctors who treat migraine patients.

More from Business

More from Scrip